Kira Gritsman

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/6b993220-5d55-11ef-92db-0be6da54f487.jpg

First Name

Kira

Last Name

Gritsman

NPI

1174598148

Faculty ID

14128

CMO Specialties

Clinical Terms

Employment Status

part-time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p><strong>The Roles of Signaling Pathways in Adult Blood Development and Leukemia</strong></p>
<p><span style="font-size: 10.5pt; font-family: Verdana, sans-serif;">The Gritsman lab studies the signal transduction pathways that affect the early fate decisions of adult hematopoietic stem cells (HSCs) as they progress from an undifferentiated multipotent state to the generation of differentiated blood cells.&nbsp; When these early fate decisions go awry, this can lead to the formation of leukemia-initiating cells. We are interested in</span><span style="font-size: 10.5pt; font-family: Verdana, sans-serif;">&nbsp;how signaling pathways affect the self-renewal and differentiation of HSCs and malignant or pre-malignant stem cells in myeloid malignancies, such as acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and myeloproliferative neoplasms (MPN).</span></p>
<p><strong>Roles of the PI3 kinase isoforms in adult blood development</strong></p>
<p>PI3 kinase (PI3K) is a lipid kinase that is important for the regulation of metabolism, the cell cycle, apoptosis, and protein synthesis. &nbsp;In hematopoietic cells, there are four isoforms of the catalytic subunit of PI3K, each encoded by a separate gene. &nbsp;Emerging evidence suggests that these isoforms have unique functions in normal and cancer cells, but may substitute for each other in some contexts.&nbsp; We have generated a series of mouse knockout models that allow us to study the roles of each of these isoforms individually in adult hematopoiesis.&nbsp; For example, we have found that the p110alpha isoform is most important for red cell development, but is not required in normal blood stem cells. We have now also generated compound knockout mice to determine the redundant roles of the PI3K isoforms in blood development. &nbsp;We recently reported that PI3K isoforms play important redundant roles during the hematopoietic stress response, such as after chemotherapy. However, deletion of all 3 Class IA PI3K isoforms leads to a phenotype with impaired HSC differentiation, resembling myelodysplastic syndrome (MDS). We are studying how deletion of PI3K will impact normal HSC function, including self-renewal, proliferation, and differentiation along different blood lineages by affecting processes such as autophagy and epigenetic regulation in HSCs.</p>
<p><strong>Roles of the PI3 kinase isoforms in leukemia</strong></p>
<p>Acute myeloid leukemia (AML) is a genetically diverse disease, but activation of the PI3K pathway has been reported in up to 80% of cases.&nbsp; A subset of AML cell lines and AML patient samples respond to PI3K pathway inhibitors, but it is unclear how patients should be selected for potential response to these inhibitors. &nbsp;We found that RAS-mutated myeloid leukemias are particularly dependent on the p110alpha isoform of PI3K, and that pharmacologic inhibition of p110alpha can be used to treat both RAS-mutated cell lines and RAS-mutated leukemia in mice. Furthermore, we use cell lines, patient samples, and mouse models of leukemia to investigate the mechanisms of resistance to PI3K inhibition, with the goal of identifying new drug targets and designing new combination treatments for leukemia that incorporate PI3K inhibitors.</p>
<p><strong>RON Kinase in Myeloproliferative Neoplasms</strong></p>
<p>The myeloproliferative neoplasms (MPNs) are a group of diseases that are caused by kinase mutations in HSCs, which lead to uncontrolled proliferation of myeloid cells. The Philadelphia chromosome-negative MPNs are characterized by mutations in the JAK/STAT signaling pathway, and respond to JAK inhibitors, but resistance often develops. We recently discovered that the receptor Tyrosine kinase RON can physically interact with JAK2 in MPN cells, leading to potentiation of JAK/STAT signaling in resistant cells. Furthermore, we found that pharmacologic or genetic inactivation of RON can inhibit proliferation of MPN cells and re-sensitize resistant cells to JAK inhibitors.</p>
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; font-size: medium; font-family: 'Times New Roman', serif;"><strong><span style="font-size: 10.5pt; font-family: Verdana, sans-serif; color: #201f1e;">Member of the Cancer Dormancy and Tumor Microenvironment Institute&nbsp;</span></strong></p>
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; font-size: medium; font-family: 'Times New Roman', serif;">&nbsp;</p>
<p class="MsoNormal" style="margin: 0in 0in 0.0001pt; font-size: medium; font-family: 'Times New Roman', serif;"><span style="font-size: 10.5pt; font-family: Verdana, sans-serif;">&nbsp;</span><span style="font-size: 10.5pt; font-family: Verdana, sans-serif;">The Gritsman lab&rsquo;s research interests include the contributions of signaling pathways to leukemic and pre-leukemic stem cell dormancy in minimal residual disease, which includes mechanisms of immune evasion. Furthermore, the Gritsman lab is interested in the roles of inflammatory signaling pathways and of the local microenvironment in bone marrow fibrosis, and in the evolution of myeloid neoplasms from the pre-malignant to malignant state. Our major goals are to identify opportunities for therapeutic targeting to prevent the transition from the pre-leukemic state to leukemia, or to eliminate minimal residual disease to prevent relapse.</span></p>

Research Areas

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

Selected Publications

<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;"><a name="_GoBack"></a><span style="font-size: 11pt; font-family: Arial, sans-serif;">Ames, K.,&nbsp;^&nbsp;Kaur,^&nbsp;I., Shi, Y., Tong, M., Sinclair, T., Hemmati, S., Glushakow-Smith, S.G., Tein,&nbsp;&nbsp;E., Gurska, L., Steidl, U., Dubin, R., Shan, J., Montagna, C., Pradhan, K., Verma, A., and&nbsp;<strong><u>Gritsman, K.</u></strong>, Deletion of PI3-Kinase Promotes Myelodysplasia Through Dysregulation of Autophagy in Hematopoietic Stem Cells,&nbsp;<strong><em>Science Advances</em></strong><em>&nbsp;2023.&nbsp;</em>doi:&nbsp;<a href="https://nam04.safelinks.protection.outlook.com/?url=https%3A%2F%2Fdoi.o…; target="_blank" rel="noopener"><span style="color: black; text-decoration: none;">10.1126/sciadv.ade8222</span></a><u>,&nbsp;</u>PMID:&nbsp;36812307</span></p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;"><em><span style="font-size: 11pt; font-family: Arial, sans-serif;">&nbsp;</span></em></p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;"><span style="font-size: 11pt; font-family: Arial, sans-serif;">Folgado Marco, V., Ames, K., Chuen, J.,&nbsp;<strong><u>Gritsman, K.</u></strong>&nbsp;&amp; Baker, N.,&nbsp;Haploinsufficiency of the essential gene&nbsp;<em>RpS12</em>&nbsp;causes defects in erythropoiesis and hematopoietic stem cell maintenance,&nbsp;<em>&nbsp;<strong>eLife</strong>&nbsp;</em>2023&nbsp;Jun 5;12:e69322. doi: 10.7554/eLife.69322.&nbsp;PMID:&nbsp;37272618</span></p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;"><span style="font-size: 11pt; font-family: Arial, sans-serif;">&nbsp;</span></p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;"><span style="font-size: 11pt; font-family: Arial, sans-serif;">Gurska, L.M., Okabe, R., Schurer, A., Tong, M.M., Soto, M., Choi, D., Ames, K., Glushakow-Smith, S., Montoya, A., Tein, E., Miles, L.A., Cheng, H., Hankey-Giblin, P., Levine, R.L., Goel, S., Halmos, B., and&nbsp;<strong><u>Gritsman, K.</u></strong>&nbsp;Crizotinib has Preclinical Efficacy in Philadelphia-negative Myeloproliferative Neoplasms,&nbsp;<strong><em>Clinical Cancer Research</em></strong>&nbsp;2022&nbsp;Dec 20:CCR-22-1763. doi: 10.1158/1078-0432.CCR-22-1763. PMID:&nbsp;36537918</span></p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;"><span style="font-size: 11pt; font-family: Arial, sans-serif;">&nbsp;</span></p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;"><span style="font-size: 11pt; font-family: Arial, sans-serif;">Gurska, L., Ames, K., and&nbsp;<strong><u>Gritsman, K</u></strong>, Signaling Pathways in Leukemic Stem Cells,&nbsp;</span><span style="font-size: 11pt; font-family: Arial, sans-serif; color: #333333; letter-spacing: 0.2pt; background-color: #fcfcfc;">In: Zhang H., Li S. (eds) Leukemia Stem Cells in Hematologic Malignancies.&nbsp;<strong>Advances in Experimental Medicine and Biology</strong>, vol 1143. Springer, Singapore</span><span style="font-size: 11pt; font-family: Arial, sans-serif;">, July 24, 2019, doi:&nbsp;<a href="https://doi.org/10.1007/978-981-13-7342-8_1"><span style="color: black; letter-spacing: 0.2pt; background-color: #fcfcfc; text-decoration: none;">https://doi.org/10.1007/978-981-13-7342-8_1</span></a><span style="letter-spacing: 0.2pt; background-color: #fcfcfc;">;&nbsp;</span>PMID:&nbsp;31338813, PMCID:&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/pmc7249489/&quot; target="_blank" rel="noopener"><span style="color: black; text-decoration: none;">PMC7249489</span></a></span></p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;">&nbsp;</p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;"><span style="font-size: 11pt; font-family: Arial, sans-serif;">Hemmati, S., Sinclair, T., Tong, M., Bartholdy, B., Okabe, R.O., Ames, K., Ostrodka, L., Haque, T., Kaur, I., Mills, T. S., Agarwal, A., Pietras, E.M., Zhao, J.J., Roberts, T.M., and&nbsp;<strong><u>Gritsman, K.</u></strong>, PI3 kinase alpha and delta promote hematopoietic stem cell activation,&nbsp;<strong><em>JCI Insight&nbsp;</em></strong>2019&nbsp;doi.org/10.1172/jci.insight.125832</span></p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;">&nbsp;</p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;"><span style="font-size: 11pt; font-family: Arial, sans-serif;">Mitchell, K., Barreyro, L., Todorova, T., Taylor, S., Antony-Debre, I., Narayanagari, S., Carvajal, L., Leite, J., Piperdi, Z., Pendurti, G., Mantzaris, I., Paietta, E., Verma, A.,&nbsp;<strong><u>Gritsman, K.,&nbsp;</u></strong>and Steidl, U. IL1RAP potentiates multiple oncogenic signaling pathways in AML,&nbsp;<strong><em>Journal of&nbsp;Experimental Medicine</em></strong><em>.&nbsp;</em>2018 May 17. doi: 10.1084/jem.20180147,&nbsp;PMID: 29773641</span></p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;">&nbsp;</p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;"><span style="font-size: 11pt; font-family: Arial, sans-serif;">Hemmati, S., Haque, T., and&nbsp;<strong><u>Gritsman, K</u>,&nbsp;</strong>Inflammatory Signaling Pathways in Pre-leukemic and Leukemic Stem Cells,&nbsp;<strong><em>Frontiers in Oncology</em></strong><em>&nbsp;</em>2017 Nov 13;7:265. doi: 10.3389/fonc.2017.00265</span></p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;">&nbsp;</p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;"><span style="font-size: 11pt; font-family: Arial, sans-serif;">Bhagat, T.D., Chen, S., Bartenstein, M., Barlowe, A.T., Von Ahrens, D., Choudhary, G.S., Tivnan, P., Amin, E., Marcondes, M., Sanders, M.A., Hoogenboezem, R.M., Kambhampati, S., Ramanchandra, N., Mantzaris, I., Sukrithan, V., Laurence, R., Lopez, R. Bhagat, P., Giricz, O., Sohal, D., Wickrema, A., Yeung, C.,&nbsp;<strong><u>Gritsman, K.,</u></strong>&nbsp;Aplan, P., Hochedlinger, K., Yu, Y., Pradhan, K., Zhang, J., Greally, J.M., Mukherjee, S., Pellagatti, A., Boultwood, J., Will, B., Steidl, U., Raaijmakers, M.H.G.P., Deeg, H.J., Kharas, M.G. and Verma, A. Epigenetically Aberrant Stroma in MDS Propagates Disease Via Wnt/b-Catenin Activation, 2017&nbsp;<strong><em>Cancer Research</em></strong>&nbsp;2017 Jul 6. pii: canres.0282.2017. doi: 10.1158/0008-5472</span></p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;">&nbsp;</p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;"><span style="font-size: 11pt; font-family: Arial, sans-serif;">Yuzugullu, H., Baitsch, L., Von, T., Steiner, A., Tong, H., Ni, J., Clayton, L., Bronson, R., Roberts, T.,&nbsp;<strong><u>Gritsman, K</u></strong><u>.</u>, and Zhao, J.J. A p110b-Rac signaling loop mediates Pten-loss-induced perturbation of hematopoiesis and leukemogenesis.&nbsp;<strong><em>Nature Communication</em></strong><em>s&nbsp;</em>October 7,2015, doi:10.1038/NCOMMS9501</span></p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;">&nbsp;</p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;"><span style="font-size: 11pt; font-family: Arial, sans-serif;">Yoda, A., Adelmant, G., Tamburini, J., Chapuy, B., Shindoh, N., Yoda, Y., Weigert, O., Kopp, N., Wu, S-C., Kim, S., Liu, H., Tivey, T., Christie, A.L.,&nbsp;<strong><u>Gritsman, K.</u></strong>,&nbsp; Gotlib, J., Deininger, M., Turley, S., Tyner, J., Marto, J., Weinstock, D.M., and Lane, A.A. Mutations in G-protein beta subunits promote transformation and kinase inhibitor resistance&nbsp;<strong><em>Nature Medicine</em></strong><em>&nbsp;</em>2015 (1):71-5.</span></p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;">&nbsp;</p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;"><strong><u><span style="font-size: 11pt; font-family: Arial, sans-serif;">Gritsman, K</span></u></strong><strong><span style="font-size: 11pt; font-family: Arial, sans-serif;">.</span></strong><span style="font-size: 11pt; font-family: Arial, sans-serif;">, Yuzugullu, H., Von, T., Yan, H., Clayton, L., Fritsch, C., Maira, S.-M., Hollingworth, G., Choi, C., Khandan, T., Paktinat, M., Okabe, R.O., Roberts, T.M., and Zhao, J.J. &nbsp;Hematopoiesis and RAS-driven myeloid leukemia differentially require PI3K isoform p110alpha<strong>.&nbsp;<em>Journal of Clinical Investigation&nbsp;</em></strong>2014;124(4):1794&ndash;1809.&nbsp;http://www.jci.org/articles/view/69927</span></p&gt;
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;">&nbsp;</p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;"><span style="font-size: 11pt; font-family: Arial, sans-serif;">Kharas, M.G. and&nbsp;<strong><u>Gritsman, K</u></strong>. Akt: A Double-Edged Sword for Hematopoietic Stem Cells.&nbsp;<strong><em>Cell Cycle</em>&nbsp;</strong>2010; Vol 9; Issue 7</span></p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;">&nbsp;</p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;"><span style="font-size: 11pt; font-family: Arial, sans-serif;">Kharas, M.G., Okabe, R., Ganis, J.J., Gozo,M., Khandan,T., Paktinat, M., Gilliland, D.G., and&nbsp;<strong><u>Gritsman, K</u>.</strong>&nbsp;Constitutively Active AKT Depletes Hematopoietic Stem Cells and Induces Leukemia in Mice.&nbsp;<strong><em>Blood&nbsp;</em></strong>2010; 115(7): 140615&nbsp;http://www.bloodjournal.org/content/115/7/1406</span></p&gt;
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;"><span style="font-size: 10.5pt; font-family: Verdana, sans-serif;">&nbsp;</span></p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;"><span style="font-size: 10.5pt; font-family: Verdana, sans-serif;">&nbsp;</span></p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;"><span style="font-family: 'Times New Roman', serif;">&nbsp;</span></p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;">&nbsp;</p>

EMR ID

73180

Is Open Scheduling

Off

David S. Geller

https://assets.montefioreeinstein.org/profiles/images/Geller_David_S_MD_2x.jpg

First Name

David

Last Name

Geller

NPI

1467437764

Faculty ID

10675

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Languages

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p>Dr. Geller is a full-time faculty member of the Orthopaedic Surgery Department at Montefiore Medical Center and serves as the director of the Orthopaedic Oncology Service, managing both pediatric and adult patients.&nbsp; He is the co-director of Orthopaedic Surgery at the Montefiore Medical Center Moses Campus and currently serves as the Quality Improvement Officer for the Montefiore Cancer Committee.&nbsp; His clinical focus involves primary and metastatic bone and soft tissue tumors, with a secondary interest in joint replacement in the setting of extensive bone loss.&nbsp; He has experience in navigation-guided surgery, allograft reconstruction, endoprosthetic reconstruction, and use of custom or patient-tailored reconstructive prostheses.&nbsp; His research interests include expression patterns in osteosarcoma, surgical margins in osteosarcoma, novel drug screening methods and targeted therapy for osteosarcoma using novel therapeutic modalities.&nbsp; He is extensively involved in resident and medical student education.</p>

Specialties

Expert Tags

Areas of Expertise

Expert Summary

<p>Dr. Geller is an orthopaedic surgeon specializing in musculoskeletal oncology and joint replacement, and his practice encompasses adult and pediatric patients. Dr. Geller’s research interests include surface receptor expression in osteosarcoma and potential targeted therapies for the treatment of osteosarcoma. He has developed a novel murine xenograft model for osteosarcoma for the evaluation of surgical margins in osseous tumor surgery. His research additionally includes allograft bone reconstruction techniques, resonance frequency changes during joint reconstruction and pain management in the elderly orthopaedic population.</p>

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

<p>Orthopedic oncology, orthopedic surgery, bone and soft tissue sarcomas, benign bone and soft-tissue tumors, metastatic carcinoma on the bone </p>

Research Focus

<p>Osteosarcoma, with an interest in innovative treatment strategies for both local disease control and metastatic disease; evaluation of expression patterns in osteosarcoma and surgical margins using a xenograft osteosarcoma murine model; the functional role of bone morphogenetic proteins in osteosarcoma surgery; use of intraoperative navigation techniques for tumor surgery; tumorigenesis of osteosarcoma </p>

Elsevier Profile

PubMed.gov URL

Selected Publications

<ul>
<li>Morris J, Dutcher J, <strong>Geller DS</strong>. Revisiting the Orhtopaedic Management of Metastatic Renal Cell Carcinoma: Rationale for a More Aggressive Approach. <em>Current Orthopaedic Practice. </em>2013 Sept/Oct; 24(5):547-551.</li>
<li>Bekarev M, Elsinger EC, Villanueva-Siles E, Borzykowski RM, <strong>Geller DS.</strong> Synovial Sarcoma of the Foot. <em>Journal of Foot and Ankle Surgery</em>. 2013 Jul-Aug; 52(4):513-7. doi: 10.1053</li>
<li>Capogna BM, Lovy A, Blum Y, Kim SJ, Flesen UR, <strong>Geller DS.</strong> Infection Rate Following Total Joint Arthroplasty in the HIV Population. <em>Journal of Arthroplasty</em>. 2013 Sep; 28(8):1254-8. doi: 10.1016</li>
<li>Lall A, Hohn E, Kim M, Gorlick R, Abraham J, <strong>Geller DS</strong>. Comparison of Surface Area Across the Allograft-Host Junction Site Using Conventional and Navigated Osteotomy Technique. <em>Sarcoma</em>. 2012; 2012:197540.&nbsp;</li>
<li>Piperdi S, Austin-Page L, <strong>Geller DS</strong>, Ahluwalia M, Gorlick S, Gill J, Sellers R, Zhang W, Li N, Ching Sohak, Gorlick R. Beta-Catenin Does Not Confer Tumorigenicity when Introduced into Partially Transformed Human Mesenchymal Stem Cells.<em> Sarcoma</em>. 2012. Epub 2012 Oct 18.</li>
<li>Crocco L, Gorlick R,<strong> Geller DS</strong>. Current Practice Management Regarding Thromboembolic Prophylaxis Within the Pediatric Sarcoma Patient Population, <em>Journal of Pediatric Hematology/Oncology</em>.2012 Sep 19. [Epub ahead of print]</li>
<li>&nbsp;Hall GL, Villanueva-Siles E, Borzykowski RM, Gruson KI, Dorfman HD, <strong>Geller</strong> <strong>DS</strong>. Aspergillus osteomyelitis of the proximal humerus: a case report. <em>Skeletal Radiology</em>. 2012 Aug; 41(8):1021-5. Epub 2012 Mar 31.</li>
<li>Sambaziotis C, Plymale M, Lovy A, O&rsquo;Halloran K, McCulloch K, <strong>Geller DS</strong>. Pseudoaneurysm of the Distal Thigh after Manipulation of a Total Knee Arthroplasty. <em>Journal of Arthroplasty</em>. 2012 Aug; 27(7); 1414.</li>
<li>Shakked RJ, <strong>Geller DS</strong>, Gorlick R, Dorfman HD. Mesenchymal chondrosarcoma: Clinicopathologic study of 20 cases. <em>The Archives of Pathology &amp; Laboratory Medicine</em>.&nbsp; 2012 Jan; 136(1):61-75.</li>
<li>Hohn E, Garfein ES, Mehta KJ, <strong>Geller DS. </strong>Quadriceps Tendon Allograft Augmentation after Wide Excision of a Soft Tissue Sarcoma. <em>Current Orthopaedic Practice</em>. 2012 Jan/Feb; 23(1):68-71.</li>
<li>Singh CK, <strong>Geller DS. </strong>The Telescopic Mating Technique for Bulk Allograft Reconstruction. <em>Orthopaedics</em>. 2012 Feb; 35(2):118-124.</li>
<li>Sambaziotis C, Lovy A, Moadel RM, Chamarthy M, Glaser J, Jaini S, Villanueva-Siles E, <strong>Geller DS</strong>. Florine-18 Fluorodeoxyglucose Positron Emission Tomography for Osteochondromas Utilizing a Triple-Time Point Protocol.&nbsp; <em>Open Journal of Medical Imaging</em>. 2011 Dec; 1(2):15-20.</li>
<li>Hassan SE, Bekarev M, Kim MY, Lin J, Piperdi S, Gorlick R, <strong>Geller DS. </strong>Cell Surface Receptor Expression Patterns in Osteosarcoma. <em>Cancer.</em> 2011 Feb 1; 118(3):740-9.</li>
<li>Plymale M, Lovy A, Villanueva-Siles E, <strong>Geller DS.</strong> Isolated intra-articular pseudorheumatoid nodule of the knee.<em> Skeletal Radiology</em>. 2011 Apr; 40(4):463-6.</li>
<li>Green MC, Dorfman HD, Villanueva-Siles E, Gorlick RG, Thornhill BA, Weber RV, <strong>Geller DS. </strong>Aggressively Recurrent Infantile Myofibroma of the Axilla and Shoulder Girdle. A Case Report. <em>Skeletal Radiology</em>.2010 Mar; 40(3):357-61.</li>
<li><strong>Geller DS</strong>, Pope JB, Thornhill BA, Dorfman, HD. Cryptococcal pyarthrosis and sarcoidosis. <em>Skeletal Radiol</em>. 2009 Jul; 38(7):721-7.</li>
<li>Sah A, <strong>Geller DS</strong>, Mankin HJ, Delaney T, Rosenberg A, Wright C, Hornicek FJ. Malignant Transformation of Synovial Chondromatosis of the Shoulder to Chondrosarcoma - A Case Report," <em>Journal of Bone and Joint Surgery. </em>2007 Jun; 89(6):1321-8.</li>
<li><strong>Geller DS</strong>, Hornicek FJ, Mankin HJ, Raskin KA. &ldquo;Soft Tissue Sarcoma Resection Volume Associated with Wound-Healing Complications,&rdquo; <em>Clinical Orthopaedics and Related Research.</em> 2007; 457:182-5.</li>
<li>Ames JA, Abraham JA, <strong>Geller DS</strong>, Goldsmith J, Gebhardt MC.&nbsp; Proximal Tibial Lesion in a Young Adult: Early Diagnosis Allowing Unique Reconstruction.&nbsp; <em>The Orthopaedic Journal at Harvard Medical School.</em> 2006 Aug: 143-7.</li>
<li>Gardner MJ, Yacoubian S, <strong>Geller DS</strong>, Pode M, Mintz D, Helfet&nbsp; DL,&nbsp; Lorich DG. &ldquo;Prediction of Soft-Tissue Injuries in Schatzker II Tibial Plateau Fractures based on Measurements of Plain Radiographs,&rdquo; <em>Journal of Trauma-Injury Infection &amp; Critical Care</em>. 2006; 60(2):319-324.</li>
<li>Steinberg EL, <strong>Geller DS</strong>, Yacoubian SV, Shasha N, Dekel S, Lorich DG. &ldquo;Intramedullary Fixation of Tibial Shaft Fractures Using an Expandable Nail,&rdquo; <em>Journal of Orthopaedic Trauma.&nbsp; </em>2006 May; 20(5):303-9.</li>
<li>Gardner, MJ, Yacoubian S, <strong>Geller DS</strong>, Suk M, Mintz D, Potter H, Helfet DL, Lorich DG. &ldquo; The Incidence of Soft Tissue Injury in Operative Tibial Plateau Fractures,&rdquo; <em>Journal of Orthopaedic Trauma</em>.&nbsp; 2005; 19:79-84.</li>
<li>Lorich DG, Yacoubian SV, <strong>Geller DS</strong>. &ldquo;Intramedullary Fixation of Humeral Shaft Fractures Using an Inflatable Nail,&rdquo; <em>Orthopaedics</em>. 2003 Oct; 26(10):1011-4.</li>
<li>Lorich DG, <strong>Geller DS</strong>, Yacoubian SV, Leo AJ, Helfet DL. &ldquo;An Innovative Mode of Intramedullary Fixation,&rdquo; <em>International Review of Modern Surgery</em>, March 2002.</li>
<li>Westrich GH, <strong>Geller DS</strong>, O&rsquo;Malley MJ, Deland JT, Helfet DL. &ldquo;Anterior Iliac Crest Bone Graft Harvesting Using the Cortico-Cancellous Reamer System,&rdquo; <em>Journal of Orthopaedic Trauma</em>. 2001 Sep-Oct; 15(7):500-6.</li>
</ul>

EMR ID

4324

Biography

<p>David S. Geller is a board-certified orthopedic oncologist who specializes in the treatment of both pediatric and adult patients with bone and soft-tissue tumors. He has been a full-time faculty member at Montefiore since 2006. He is an Associate Professor of Orthopedic Surgery and Pediatrics at our Albert Einstein College of Medicine.</p><p>Dr. Geller is known for his expertise in musculoskeletal tumor surgery, with specific experience in bone and soft-tissue sarcomas, such as osteosarcoma, Ewing's sarcoma, liposarcoma and synovial sarcoma. He has extensive experience in managing patients with metastatic carcinoma of the bone as well. He routinely offers limb-salvage surgery using a wide array of reconstructive tools.</p><p>Dr. Geller earned his medical degree from Tel Aviv University's Sackler School of Medicine and completed an orthopedic surgery residency at Montefiore. He received his fellowship training from the Harvard Combined Orthopedic Oncology Program, which included Massachusetts General Hospital, Boston Children's Hospital, and Beth Israel Deaconess Medical Center.</p><p>Dr. Geller serves as the Associate Director of the Musculoskeletal Oncology Research Laboratory at Montefiore. He leads numerous translational research efforts designed to investigate the pathophysiology and molecular mechanisms of bone and soft tissue cancers. He is interested in improved surgical techniques and novel therapeutic approaches for primary malignant bone tumors. He is actively involved in collaborative clinical trials both nationally and internationally.</p><p>Dr. Geller is an active member of the American Academy of Orthopedic Surgeons, Muskuloskeletal Tumor Society, Connective Tissue Oncology Society, Children's Oncology Group, American Orthopedic Association, and the American Association for Cancer Research.</p>

Is Open Scheduling

Off

Ellen Wolkin Friedman

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/5f748650-3937-11ed-a06a-83625b154202.jpg

First Name

Ellen

Last Name

Friedman

NPI

1215026539

Faculty ID

2007

CMO Specialties

Clinical Terms

Employment Status

part-time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p>Dr. Ellen Friedman&rsquo;s passion is the study of the blood (hematology) and ensuring that the next generation of medical practitioners are prepared to analyze and treat blood-related problems.</p>
<p>Dr. Friedman has been the Hematology Fellowship Director of Montefiore Medical Center/Albert Einstein College of Medicine since 2005. She completed a fellowship in hematology at New York University, specializing in the conditions of red cells, platelets and hematologic malignancies. She has been engaged in diagnosing and treating these conditions while simultaneously teaching medical students, medical residents and fellows in the skills and knowledge required. She trained at New York Hospital/Cornell, Bellevue, New York University and has been an attending physician in teaching programs in New York City her entire career. She has 40 years of experience in caring for patients in the Bronx both in the city hospitals and at Montefiore/Albert Einstein College of Medicine. Dr. Friedman also educates patients, lecturing nationally for National Organization of Rare Diseases and the Aplastic Anemia &amp; MDS International Foundation.</p>
<p>Dr. Friedman was elected Fellow in the American College of Physicians and is an Associate Professor of Clinical Medicine at Einstein. Her teaching has been recognized with the Best Teacher Award by the hematology-oncology fellows. Her research has focused on a variety of blood conditions including anemia, thrombocytopenia, myelodysplastic syndrome, and the safe performance of the bone marrow procedure.</p>

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Selected Publications

<ol>
<li>Dai, T, Friedman E, Barta S. Ruxolitinib Withdrawal Syndrom Leading to Tumor Lysis. JCO 2013 June 10.</li>
<li>Lam A, Guandabolu K, Sridharan A, Jain R, Pavlos M, Chrysofakis G, Yu Y, Friedman, E, Price E, Schrier S, Verma A. Multiplicative Interaction Between Mean Corpuscular Volume and Red Cell Distribution Width in Predicting Mortality of Elderly Patients with and without Anemia. American Journal of Hematology, 2013 July 5.</li>
<li>Bhavana Konda, Swati Pathak, Inga Edwin, Priti Mishall, Sherry A. Downie, Todd R. Olson, Louis J. Reed and Ellen W. Friedman. Safe and Successful Bone Marrow Biopsy: An Anatomical and CT-Based Cadaver Study. Am. J. Hematol. 00:000-000, June 2014.</li>
</ol>

EMR ID

3276

Is Open Scheduling

Off

Daniel T. Friedman

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/880f93d0-7e92-11ec-9d5a-db3fba8c54fb.jpg

First Name

Daniel

Last Name

Friedman

NPI

1538180252

Faculty ID

14639

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

4745

Biography

<p>Daniel T. Friedman, MD, is Director, Community Hematology/Oncology at Montefiore Einstein and Assistant Professor, Medical Oncology at our Albert Einstein College of Medicine. He delivers community-focused care for hematology and medical oncology patients in the Bronx and Yonkers.</p><p>After earning his Doctor of Medicine from Cornell University Medical College in 1999, Dr. Friedman completed his internship and residency in internal medicine at Montefiore Einstein in 2002. He remained at Montefiore Einstein to complete an oncology fellowship in 2005.</p><p>Dr. Friedman's research has been focused on treatment outcomes and access to care. His work has been published in peer-reviewed journals and abstracts.</p><p>Dr. Friedman is board certified in Medical Oncology and Hematology.</p>

Is Open Scheduling

Off

Susanna Curtis

https://assets.montefioreeinstein.org/profiles/images/16593-susanna-curtis.jpg

First Name

Susanna

Last Name

Curtis

NPI

1154683449

Faculty ID

16593

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Titles

Locations

Education and Trainings

Research Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

Is Open Scheduling

Off

Haiying Cheng

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/14529c70-3608-11ed-8123-8ffce84a9f6a.jpg

First Name

Haiying

Last Name

Cheng

NPI

1689724965

Faculty ID

13426

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

5611

Is Open Scheduling

Off

Mark H. Chaitowitz

https://assets.montefioreeinstein.org/profiles/images/default-profile-blue.svg

First Name

Mark

Last Name

Chaitowitz

NPI

1922215680

Faculty ID

14005

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p>Dr. Mark Chaitowitz obtained his medical degree at the University of Witwatersrand in Johannesburg, South Africa. He relocated to the United States in 2001, where he completed his residency in internal medicine at Albert Einstein Medical Center, and fellowship in hematology and oncology at Thomas Jefferson University Hospital, both in Philadelphia.</p>
<p>In 2013 Dr. Chaitowitz joined the Division of Hematology as an Assistant Professor. He sees patients with a wide range of blood disorders, both benign and malignant. He has a special interest in platelet disorders, as well as in the management of iron deficiency anemia, his area of clinical research.</p>

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

Selected Publications

<ol>
<li>Zheng, C. Y. Minniti, C. P. Chaitowitz, M. H., Sickle cell crisis complicated by synthetic cannabinoid abuse: a case report, Hemoglobin, 2016, accepted for publication.</li>
<li>Scott, E., U. Borate, S. Heitner, M. Chaitowitz, W. Tester, and G. Eiger, Pain Management Practices by Internal Medicine Residents: A Comparison Before and After Educational and Institutional Interventions, American Journal of Hospice and Palliative Medicine, 2009; 25(6): 431-439.&nbsp;</li>
<li>Chaitowitz, M. H., A. Ferber and N. Flomenberg, Patient-reported experience of chemotherapy: expectations vs. reality, Journal of Clinical Oncology, 2008; 26 (May 20 suppl; abstr 20686).</li>
<li>Darabi, K. Sieber, M. Chaitowitz, M. Braitman, L. Tester, W. Diehl, V. Infradiaphragmatic versus supradiaphragmatic Hodgkin lymphoma: A retrospective review of 1,114 patients. Leukemia and Lymphoma, 2005; 46(12): 1715-1720.&nbsp;</li>
<li>Chaitowitz, M., W. Tester and G. Eiger, Use of a comprehensive survey as a first step in addressing clinical competence of physicians-in-training in the management of pain, Journal of Opioid Management, 2005 May/June; 98-108.</li>
<li>Chaitowitz, M., M.L. Shaw and T.R. Mokoena, Gastrointestinal cryptococcosis presenting as spontaneous jejunal perforation in a nonimmunocompromised host, Digestive Disease and Science, 2003; 48(6): 1196-1199.</li>
</ol>

EMR ID

5733

Is Open Scheduling

Off

Enrico Castellucci

https://assets.montefioreeinstein.org/profiles/images/physphoto/Castellucci_Enrico_MD_420x504.jpg

First Name

Enrico

Last Name

Castellucci

NPI

1821354622

Faculty ID

17784

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

76764

Is Open Scheduling

Off

Henny H. Billett

https://assets.montefioreeinstein.org/profiles/images/physphoto/Billett_Henny_MD_420x504.jpg

First Name

Henny

Last Name

Billett

NPI

1689755001

Faculty ID

6411

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p>Dr. Henny Billett has been Chief of the Division of Hematology since 2012 and Professor of Clinical Medicine and Pathology since 2002.</p>
<p>Dr. Billett's clinical research interests are in risk factors for thrombosis and microvascular disease, with emphasis on epidemiological aspects and outcomes research.</p>
<p>Recent investigations have focused on:</p>
<ol>
<li>Hemolysis patterns in CF-LVAD patients and their association with device thrombosis (collaboration with Dr. Ulrich Jorde, Cardiology)</li>
<li>Evaluation of CNS function and cognition in patients with sickle cell disease (collaboration with Dr. Craig Branch, Gruss Magnetic Resonance Research Center)</li>
<li>Priapism in murine and human models of sickle cell (collaboration with Dr. Kelvin Davies)</li>
<li>Multicenter studies
<ul>
<li>P-Selectin therapy in sickle cell disease</li>
<li>Viral co-infections, paraproteinemia and thrombosis</li>
</ul>
</li>
</ol>
<p>Dr. Billett completed an undergraduate degree from the University of Pennsylvania cum laude; medical school Mount Sinai School of Medicine; and an MSc from the London School of Hygiene and Tropical Medicine in London. She was a Senior House Officer at St. Bartholomew's Hospital, London, and completed her training at Montefiore.</p>

Research Areas

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

Selected Publications

<ol>
<li>Park D, Southern W, Calvo M, Kushnir M, Solorzano C, Sinnett M, <strong>Billett HH</strong>. Treatment with Dalteparin is Associated with a Lower Risk of Bleeding Compared to Treatment with Unfractionated Heparin in Patients with Renal Insufficiency. J Gen Intern Med. 2016; 31(2):182-7. PubMed [journal]PMID: 26209179 PMCID: PMC4720650</li>
<li>Jou, E, Glichich G, Chan ACY, Mohan D, Felson UR, Ayyappan S, <strong>Billett HH</strong>, Hui E, Chan ATC, Raghupathy R. Viral Co-Infections and Paraproteins in HIV: Effect on Development of Hematological Malignancies. Ann Hematol. 2016 Jan 9. [Epub ahead of print] PMID: 26747296</li>
<li>Broder A, Mowrey W, Kim M, Murakhovskaya I, <strong>Billett HH</strong>, Neugarten J, Costenbader KH, Putterman C.Association between Antiphospholipid Antibodies and All-Cause Mortality among End-Stage Renal Disease Patients with and without SLE: a retrospective cohort study. Rheumatology 2015 Dec 24. pii: kev423. [Epub ahead of print] PubMed PMID: 26705328.&nbsp;</li>
<li>Naymagon H, Pendurti G, <strong>Billett HH</strong>. Acute Splenic sequestration crisis in adult sickle cell disease: A report of 16 cases. Hemoglobin. 2015;39:375-9.</li>
<li>Curtis SA, Etzion Z, Danda NA, Cohen HW, <strong>Billett HH</strong>. Elevated steady state WBC and platelet counts are associated with frequent emergency room use in adults with sickle cell anemia. PLoS One.</li>
</ol>

EMR ID

3198

Is Open Scheduling

Off

Jesus D. Anampa Mesias

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/f27dbf80-2ee1-11ed-bcda-4d15024a9ee0.jpg

First Name

Jesus

Last Name

Anampa Mesias

NPI

1356590772

Faculty ID

14446

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p><span style="font-size: 10.5pt; font-family: Verdana, sans-serif;">Dr. Jesus Anampa is an Associate Professor of Medicine in the Department of Medical Oncology at Albert Einstein College of Medicine/ Montefiore Medical Center. Dr. Anampa is the Clinical Research Leader for Breast Oncology at Montefiore Medical Center and The Phase I Liaison for Breast Oncology.</span></p>
<p><span style="font-size: 10.5pt; font-family: Verdana, sans-serif;">A native of Peru, Dr. Anampa finished medical school at Universidad Peruana Cayetano Heredia in Lima, Peru, and successfully finished Internal Medicine Residency at Rochester General Hospital in Rochester, NY. Dr. Anampa initially joined Albert Einstein College of Medicine/Montefiore Medical Center to complete his fellowship in hematology/oncology and then joined our medical oncology faculty team at AECOM/MMC. In 2018, he obtained a Master&rsquo;s of Science degree &ldquo;with distinction&rdquo; in clinical research from Albert Einstein College of Medicine. Dr. Anampa is a practicing physician who specializes in breast medical oncology and clinical &amp; translational cancer research.&nbsp;</span></p>
<p><span style="font-size: 10.5pt; font-family: Verdana, sans-serif;">&nbsp;</span></p>
<p><strong><u><span style="font-size: 10.5pt; font-family: Verdana, sans-serif;">Tumor MicroEnvironment of Metastasis</span></u></strong><u></u></p>
<p><span style="font-size: 10.5pt; font-family: Verdana, sans-serif;">Dr. Anampa is currently working with the tumor microenvironment (TME) program at Albert Einstein College of Medicine, which is a nationwide well-recognized program, lead by Dr. John Condeelis, evaluating new mechanisms of cancer intravasation and dissemination. Dr. Anampa plays an important role in translating bench-to-bedside and bedside-to-bench research in our TME program, and currently, he is working on the Tumor microenvironment of metastasis (TMEM) and its significance as a biomarker in breast cancer. Dr. Anampa is the principal investigator of a novel phase I trial targeting the tumor microenvironment to prevent metastasis. In addition, Dr. Anampa is leading a clinical trial to validate a novel imaging technique to identify metastasis doorways (TMEM) in vivo using MRI in patients with breast cancer.</span></p>
<p><span style="font-size: 10.5pt; font-family: Verdana, sans-serif;"><a href="https://clinicaltrials.gov/ct2/show/NCT03694756">https://clinicaltrials…;
<p><span style="font-size: 10.5pt; font-family: Verdana, sans-serif;"><a href="https://clinicaltrials.gov/ct2/show/NCT02824575">https://clinicaltrials…;
<p><span style="font-size: 10.5pt; font-family: Verdana, sans-serif;">&nbsp;</span></p>
<p><strong><u><span style="font-size: 10.5pt; font-family: Verdana, sans-serif;">Breast Cancer and Obesity</span></u></strong><u></u></p>
<p><span style="font-size: 10.5pt; font-family: Verdana, sans-serif;">Dr. Anampa is working with the diabetes center at Albert Einstein to identify pathways associated with obesity and breast cancer. Preclinical studies at our institution have demonstrated that the CDK4/6-Rb pathway is affected in diet-induced obesity in mouse models. Dr. Anampa is leading a clinical trial that assesses the effect of CDK 4/6 inhibitors on body composition in patients with metastatic breast cancer.</span></p>
<p><span style="font-size: 10.5pt; font-family: Verdana, sans-serif;"><a href="https://clinicaltrials.gov/ct2/show/NCT03697577">https://clinicaltrials…;
<p><span style="font-size: 10.5pt; font-family: Verdana, sans-serif;">&nbsp;</span></p>
<p><strong><u><span style="font-size: 10.5pt; font-family: Verdana, sans-serif;">Clinical/Translational Research Leadership</span></u></strong><u></u></p>
<p><span style="font-size: 10.5pt; font-family: Verdana, sans-serif;">Dr. Anampa is The Clinical Research Leader for Breast Oncology at Montefiore Medical Center/AECOM and he serves as local principal investigator for several Phase I, II, and III trials. In addition, Dr. Anampa is also a member of the Protocol Review and monitoring committee at Montefiore Medical Center/AECOM.</span></p>
<p><span style="font-size: 10.5pt; font-family: Verdana, sans-serif;">Dr. Anampa serves as the Montefiore Principal Investigator for the Translational Breast Cancer Research symposium (TBCRC) and the (I-Spy2)</span></p>
<p><span style="font-size: 10.5pt; font-family: Verdana, sans-serif;">Dr. Anampa is a native Spanish-speaker and has an innate passion for breast cancer research, with an ultimate goal to expand breast cancer therapeutic options and improve breast cancer outcomes. Dr. Anampa is also interested in breast cancer research and is always eager to participate in community activities related to breast cancer.</span></p>
<p>&nbsp;</p>
<p><span style="font-size: 10.5pt; font-family: Verdana, sans-serif;">During his free time, Dr. Anampa enjoys mountain biking and soccer.</span></p>

Research Areas

Specialties

Expert Tags

Areas of Expertise

Expert Summary

<p>Dr. Anampa is a breast medical oncologist and a member of the Tumor Microenvironment and Metastasis (TMEM) research program at Albert Einstein College of Medicine, which focuses on targeting the tumor microenvironment as a mechanism to prevent the spread of breast cancer.
He is fluent in Spanish and enjoys participating in bilingual community activities about cancer prevention and treatment in the Bronx.</p>

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Breast cancer, medical oncology, clinical trials

Research Focus

Tumor micro-environment of metastasis and breast cancer; breast cancer immunology, new mechanisms of metastasis, cancer among minorities, breast cancer risk and outcomes among women with HIV

Elsevier Profile

EMR ID

56774

Biography

<p>Jesus Anampa Mesias, MD is a medical oncologist at Montefiore Einstein Comprehensive Cancer Center and a member of its Cancer Therapeutics Research Program focused on identifying new treatment targets and novel cancer therapeutics. He is fluent in Spanish and enjoys participating in bilingual community activities about cancer prevention and treatment in our community.</p><p>Dr. Anampa Mesias received his medical degree from the Universidad Peruana Cayetano Heredia in Lima, Peru, completed his residency in internal medicine at Rochester General Hospital in Rochester, NY, and completed a medical oncology/clinical hematology fellowship at Montefiore Medical Center. He remained at Albert Einstein as a research fellow before joining the medical oncology team at Montefiore.</p><p> </p>

Is Open Scheduling

Off